Data protection Impressum

R&D

Release Therapeutics has raised CHF 3.3 million in seed funding to advance its innovative approach to treating metachromatic leukodystrophy (MLD), a rare genetic disorder affecting young children.

Release Therapeutics secures CHF 3.3 million to advance MLD research

13 August 2024

CSEM, along with start-ups Impli and Yalosys, has developed CERES, an implantable biosensor for real-time fertility hormone monitoring.

CSEM develops a pioneering implant to support reproductive medicine

7 August 2024

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (June 2024)

26 June 2024

Three heritage buildings in Neuchâtel are nearing completion with 33,300 solar tiles from CSEM and Freesuns, marking significant progress in the 2050 energy transition.

Neuchâtel equips heritage buildings with innovative solar roof tiles

25 June 2024

Switzerland ranks as the second most competitive country in the 2024 IMD World Competitiveness Ranking, demonstrating significant improvements in economic performance and business efficiency.

Business environment

Switzerland secures second spot in IMD’s 2024 World Competitiveness Ranking

19 June 2024

Researchers at EPFL have introduced ChemCrow, a revolutionary AI system that integrates 18 advanced tools, significantly enhancing efficiency in chemical research.

EPFL scientists unveil a groundbreaking AI for chemical synthesis

22 May 2024

An EPFL research project has developed a method based on machine learning to quickly and accurately search large databases, leading to the discovery of 14 new materials for solar cells.

EPFL uses machine learning to discover new solar-cell materials

21 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

1 2 3 4 5 6 7 8 … 13